EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1128	wallach.in. or ramakrishnan.in. or "shmushkovich.in"	US-PGPUB; USPAT	OR	OFF	2007/03/22 22:05
L2	91	l1 and (nik or (NF-kappa B-inducing kinase))	US-PGPUB; USPAT	OR	OFF	2007/03/22 22:08
L3	200	IL-2 near6 (nik or (NF-kappa B-inducing kinase))	US-PGPUB; USPAT	OR	OFF	2007/03/22 22:08
L4	2	l2 and l3	US-PGPUB; USPAT	OR	OFF	2007/03/22 22:08

About Entrez
Text Version
Entrez PubMed Overview
Help | FAQ
Tutorials
New/Noteworthy
E-Utilities
PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
Special Queries
LinkOut
My NCBI
Related Resources
Order Documents
NLM Mobile
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

All: 95 Review: 95
Selected: 8

Items 81 - 95 of 95 Previous Page 5 of 5

81: Shand N, Richardson B. Related Articles, Links

Sandimmun (cyclosporin A): mode of action and clinical results in rheumatoid arthritis.
Scand J Rheumatol Suppl. 1988;76:265-78. Review.
PMID: 3075082 [PubMed - indexed for MEDLINE]

82: Ostensen M, Forre O. Related Articles, Links

Modulation of human natural killer cell function by cytokines and rheumatic disease.
Scand J Rheumatol Suppl. 1988;76:183-8. Review.
PMID: 3075075 [PubMed - indexed for MEDLINE]

83: Kitas GD, Salmon M, Allan IM, Bacon PA. Related Articles, Links

The T cell system in rheumatoid arthritis: activated or defective?
Scand J Rheumatol Suppl. 1988;76:161-73. Review.
PMID: 3075073 [PubMed - indexed for MEDLINE]

84: Forre O, Waalen K, Natvig JB, Kjeldsen-Kragh J. Related Articles, Links

Evidence for activation of rheumatoid synovial T lymphocytes--development of rheumatoid T cell clones.
Scand J Rheumatol Suppl. 1988;76:153-60. Review.
PMID: 3075072 [PubMed - indexed for MEDLINE]

85: Kolarz G. Related Articles, Links

Pathogenesis of rheumatoid arthritis.
Acta Med Austriaca. 1988;15(5):128-30. Review.
PMID: 2464266 [PubMed - indexed for MEDLINE]

86: Kucharz EJ. Related Articles, Links

[Plasma inhibitors of interleukin 2 in normal conditions and in

pathological states]
Wiad Lek. 1987 Aug 15;40(16):1111-5. Review. Polish. No abstract available.
PMID: 3326287 [PubMed - indexed for MEDLINE]

87: Arenzana-Seisdedos F, Teyton L, Virelizier JL. Related Articles, Links

Immunoregulatory mediators in the pathogenesis of rheumatoid arthritis.
Scand J Rheumatol Suppl. 1987;66:13-7. Review.
PMID: 3131870 [PubMed - indexed for MEDLINE]

88: Emery P, Williamson DJ, Mackay IR. Related Articles, Links

Role of cytokines in rheumatological inflammation.
Concepts Immunopathol. 1987;4:171-99. Review. No abstract available.
PMID: 2439208 [PubMed - indexed for MEDLINE]

89: Sibbitt WL Jr, Bankhurst AD. Related Articles, Links

Natural killer cells in connective tissue disorders.
Clin Rheum Dis. 1985 Dec;11(3):507-21. Review.
PMID: 3907953 [PubMed - indexed for MEDLINE]

90: Talal N. Related Articles, Links

Interleukins, interferon and rheumatic disease.
Clin Rheum Dis. 1985 Dec;11(3):633-44. Review. No abstract available.
PMID: 2416506 [PubMed - indexed for MEDLINE]

91: Stecher VJ, Carlson JA, Connolly KM, Bailey DM. Related Articles, Links

Disease-modifying antirheumatic drugs.
Med Res Rev. 1985 Jul-Sep;5(3):371-90. Review. No abstract available.
PMID: 3894835 [PubMed - indexed for MEDLINE]

92: Pichler WJ, Emmendorffer A, Peter HH, Deicher HR, Fontana A, de Weck AL. Related Articles, Links

[Analysis of T-cell subpopulations. Pathophysiological concept and significance for clinical medicine]
Schweiz Med Wochenschr. 1985 Apr 20;115(16):534-50. Review. German.
PMID: 3159084 [PubMed - indexed for MEDLINE]

93: Boumpas DT, Tsokos GC. Related Articles, Links

Pathophysiologic aspects of lymphokines.
Clin Immunol Rev. 1985;4(2):201-40. Review.
PMID: 2417771 [PubMed - indexed for MEDLINE]

94: Alarcon-Segovia D. Related Articles, Links

Mixed connective tissue disease: a disorder of immune regulation.
Semin Arthritis Rheum. 1983 Aug;13(1 Suppl 1):114-20. Review. No abstract available.
PMID: 6226095 [PubMed - indexed for MEDLINE]

95: Mizel SB. Related Articles, Links

Biochemical and biological characterization of lymphocyte-activating factor (LAF) produced by the murine macrophage cell line, P388D.
Ann N.Y Acad Sci. 1979;332:539-49. Review. No abstract available.
PMID: 231409 [PubMed - indexed for MEDLINE]

Items 81 - 95 of 95 Previous Page 5 of 5

Display Summary Show 20 Sort by Send to

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Privacy Statement | Freedom of Information Act | Disclaimer

Mar 19 2007 07:18:03

1: Sanchez-Valdepenas C, Martin AG, Ramakrishnan P, Wallach D, Fresno M. Related Articles, Links

NF-kappaB-inducing kinase is involved in the activation of the CD28 responsive element through phosphorylation of c-Rel and regulation of its transactivating activity.
J Immunol. 2006 Apr 15;176(8):4666-74.
PMID: 16585559 [PubMed - indexed for MEDLINE]

2: Lu LF, Gondek DC, Scott ZA, Noelle RJ. Related Articles, Links

NF kappa B-inducing kinase deficiency results in the development of a subset of regulatory T cells, which shows a hyperproliferative activity upon glucocorticoid-induced TNF receptor family-related gene stimulation.
J Immunol. 2005 Aug 1;175(3):1651-7.
PMID: 16034105 [PubMed - indexed for MEDLINE]

3: Matsumoto M, Yamada T, Yoshinaga SK, Boone T, Horan T, Fujita S, Li Y, Mitani T. Related Articles, Links

Essential role of NF-kappa B-inducing kinase in T cell activation through the TCR/CD3 pathway.
J Immunol. 2002 Aug 1;169(3):1151-8.
PMID: 12133934 [PubMed - indexed for MEDLINE]

4: Yamada T, Mitani T, Yorita K, Uchida D, Matsushima A, Iwamasa K, Fujita S, Matsumoto M. Related Articles, Links

Abnormal immune function of hemopoietic cells from alymphoplasia (aly) mice, a natural strain with mutant NF-kappa B-inducing kinase.
J Immunol. 2000 Jul 15;165(2):804-12.
PMID: 10878354 [PubMed - indexed for MEDLINE]

5: O'Neill LA, Greene C. Related Articles, Links

Signal transduction pathways activated by the IL-1 receptor family: ancient signaling machinery in mammals, insects, and plants.
J Leukoc Biol. 1998 Jun;63(6):650-7. Review.
PMID: 9620655 [PubMed - indexed for MEDLINE]

Mar 19 2007 07:18:03

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	"5854003".pn.	US-PGPUB; USPAT	OR	OFF	2007/03/22 20:32
L2	3	(NF-kappa B-inducing kinase or NIK) near8 (IL-2 or IL2)	US-PGPUB; USPAT	ADJ	OFF	2007/03/22 20:46

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTASXS1656

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 DEC 18 CA/CAplus pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 4 DEC 18 CA/CAplus patent kind codes updated
NEWS 5 DEC 18 MARPAT to CA/CAplus accession number crossover limit increased
to 50,000
NEWS 6 DEC 18 MEDLINE updated in preparation for 2007 reload
NEWS 7 DEC 27 CA/CAplus enhanced with more pre-1907 records
NEWS 8 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS 9 JAN 16 CA/CAplus Company Name Thesaurus enhanced and reloaded
NEWS 10 JAN 16 IPC version 2007.01 thesaurus available on STN
NEWS 11 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS 12 JAN 22 CA/CAplus updated with revised CAS roles
NEWS 13 JAN 22 CA/CAplus enhanced with patent applications from India
NEWS 14 JAN 29 PHAR reloaded with new search and display fields
NEWS 15 JAN 29 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 16 FEB 15 PATDPASPC enhanced with Drug Approval numbers
NEWS 17 FEB 15 RUSSIAPAT enhanced with pre-1994 records
NEWS 18 FEB 23 KOREAPAT enhanced with IPC 8 features and functionality
NEWS 19 FEB 26 MEDLINE reloaded with enhancements
NEWS 20 FEB 26 EMBASE enhanced with Clinical Trial Number field
NEWS 21 FEB 26 TOXCENTER enhanced with reloaded MEDLINE
NEWS 22 FEB 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements
NEWS 23 FEB 26 CAS Registry Number crossover limit increased from 10,000

to 300,000 in multiple databases
NEWS 24 MAR 15 WPIDS/WPIX enhanced with new FRAGHITSTR display format
NEWS 25 MAR 16 CASREACT coverage extended
NEWS 26 MAR 20 MARPAT now updated daily
NEWS 27 MAR 22 LWPI reloaded

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 20:52:45 ON 22 MAR 2007

=> File Medline EMBASE Biosis Caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 20:53:02 ON 22 MAR 2007

FILE 'EMBASE' ENTERED AT 20:53:02 ON 22 MAR 2007

FILE 'BIOSIS' ENTERED AT 20:53:02 ON 22 MAR 2007

FILE 'CAPLUS' ENTERED AT 20:53:02 ON 22 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

=> s (NF-kappa B-inducing kinase or NIK) (8A) (IL-2 or IL2)
L1 10 (NF-KAPPA B-INDUCING KINASE OR NIK) (8A) (IL-2 OR IL2)

```
=> duplicate
ENTER REMOVE, IDENTIFY, ONLY, OR (?):remove
ENTER L# LIST OR (END):l1
DUPLICATE PREFERENCE IS 'MEDLINE, EMBASE, BIOSIS, CAPLUS'
KEEP DUPLICATES FROM MORE THAN ONE FILE?  Y/(N):n
PROCESSING COMPLETED FOR L1
L2             4 DUPLICATE REMOVE L1 (6 DUPLICATES REMOVED)

=> d l2 1-4 bib ab

L2   ANSWER 1 OF 4     MEDLINE on STN                    DUPLICATE 1
AN   2006187607     MEDLINE
DN   PubMed ID: 16585559
TI   NF-kappaB-inducing kinase is involved in the activation of the
CD28
     responsive element through phosphorylation of c-Rel and
regulation of its
     transactivating activity.
AU   Sanchez-Valdepenas Carmen; Martin Angel G; Ramakrishnan
Parameswaran;
     Wallach David; Fresno Manuel
CS   Centro de Biologia Molecular, Consejo Superior de Investigaciones
     Cientificas, Universidad Autonoma de Madrid, Madrid, Spain.
SO   Journal of immunology (Baltimore, Md. : 1950), (2006 Apr 15)
Vol. 176, No.
     8, pp. 4666-74.
     Journal code: 2985117R. ISSN: 0022-1767.
CY   United States
DT   Journal; Article; (JOURNAL ARTICLE)
     (RESEARCH SUPPORT, NON-U.S. GOV'T)
LA   English
FS   Abridged Index Medicus Journals; Priority Journals
EM   200605
ED   Entered STN: 5 Apr 2006
     Last Updated on STN: 17 May 2006
     Entered Medline: 16 May 2006
AB   Previous evidence suggested that NF-kappaB-inducing kinase (NIK)
     might regulate IL-2 synthesis.  However, the molecular
     mechanism is not understood.  In this study, we show that NIK is
     involved in CD3 plus CD28 activation of IL-2
     transcription.  Splenic T cells from aly/aly mice (that have a
defective
     NIK protein) have a severe impairment in IL-2
     and GM-CSF but not TNF secretion in response to CD3/CD28.  This
effect
     takes place at the transcriptional level as overexpression of
alyNIK
     inhibits IL-2 promoter transcription.  NIK activates the CD28
     responsive element (CD28RE) of the IL-2 promoter and
     strongly synergizes with c-Rel in this activity.  We found that
NIK
```

interacts with the N-terminal domain of c-Rel, mapping this interaction to aa 771-947 of NIK. Moreover, NIK phosphorylates the c-Rel C-terminal transactivation domain (TAD) and induces Gal4-c-Rel-transactivating activity. Anti-CD28 activated Gal4-c-Rel transactivation activity, and this effect was inhibited by a NIK-defective mutant. Deletion studies mapped the region of c-Rel responsive to NIK in aa 456-540. Mutation of several serines, including Ser471, in the TAD of c-Rel abrogated the NIK-enhancing activity of its transactivating activity. Interestingly, a Jurkat mutant cell line that expresses one of the mutations of c-Rel (Ser471Asn) has a severe defect in IL-2 and CD28RE-dependent transcription in response to CD3/CD28 or to NIK. Our results support that NIK may be controlling CD28RE-dependent transcription and T cell activation by modulating c-Rel phosphorylation of the TAD. This leads to more efficient transactivation of genes which are dependent on CD28RE sites where c-Rel binds such as the IL-2 promoter.

L2 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:837297 CAPLUS
DN 139:312400
TI Modulation of NIK with IL-2 common γ chain and therapeutic uses thereof
IN Wallach, David; Ramakrishnan, Parameswaran; Shmushkovich, Taisia
PA Yeda Research and Development Co.Ltd, Israel
SO PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087380	A1	20031023	WO 2003-IL317	20030415

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2482387 A1 20031023 CA 2003-2482387 20030415
AU 2003226607 A1 20031027 AU 2003-226607 20030415
EP 1499729 A1 20050126 EP 2003-746399 20030415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2005530491 T 20051013 JP 2003-584319 20030415
US 2005272633 A1 20051208 US 2005-511314 20050517
PRAI IL 2002-149217 A 20020418
IL 2002-152183 A 20021008
WO 2003-IL317 W 20030415

AB This invention relates to the use of NIK and related mols. for the modulation of signal activities controlled by cytokines, and some new such mols. In addition the invention relates to the use of a DNA encoding NIK, or its antisense , NIK specific antibodies, a small mol. obtainable by screening products of combinatorial chemical in a luciferase system, for modulating the interaction between IL-2 common gamma chain (cγc) and NIK. The present invention also relates to the use of NIK or a mutein, variant, fusion protein, functional derivative, circularly permutated derivative or fragment thereof, in the manufacture of a medicament for the treatment of a disease, wherein a cytokine stimulating signalling trough the IL-2 cγc is involved in the pathogenesis of

the disease.
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:837291 CAPLUS
DN 139:328743
TI Modulating interaction of IL-2 with NIK by derivatives of the IL-2 common gamma chain, and therapeutic uses thereof
IN Wallach, David; Ramakrishnan, Parameswaran; Shmushkovich, Taisia
PA Yeda Research and Development Co. Ltd., Israel
SO PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087374	A1	20031023	WO 2003-IL316	20030415
WO 2003087374	A9	20050127		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2482718	A1	20031023	CA 2003-2482718	20030415
AU 2003222415	A1	20031027	AU 2003-222415	20030415
EP 1499724	A1	20050126	EP 2003-717504	20030415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2005525113 T 20050825 JP 2003-584315 20030415
US 2005287144 A1 20051229 US 2005-511722 20050622
PRAI IL 2002-149217 A 20020418
IL 2002-152183 A 20021008
WO 2003-IL316 W 20030415
AB This invention relates to the use of IL-2 common gamma chain (cγc) and related mols. for the modulation of signal activities controlled by cytokines, and therapeutic uses thereof. Specifically, the invention relates to the use of IL-2 cγc or a mutein, variant, fusion protein, the intracellular domain of cγc (ICDcγc), 1-357, 1-341 functional derivative, circularly permutated derivative or fragment thereof for modulating the interaction between cγc and NIK. In addition the invention relates to the use of a DNA encoding cγc or derivs., a DNA encoding the antisense of cγc, an antibody specific to cγc, or a small mol. obtainable by screening products of combinatory chemical in a luciferase system, for modulating the interaction between IL-2 common gamma chain (cγc) and NIK. In another aspect, the invention provides the use of cγc or derivs. in the manufacture of a medicament for treatment of a disease, wherein NIK activity is involved in the pathogenesis of the disease.
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 4 MEDLINE on STN DUPLICATE 2
AN 2002385095 MEDLINE
DN PubMed ID: 12133934
TI Essential role of NF-kappa B-inducing kinase in T cell activation through the TCR/CD3 pathway.
AU Matsumoto Mitsuru; Yamada Takuji; Yoshinaga Steven K; Boone Tom; Horan Tom; Fujita Shigeru; Li Yi; Mitani Tasuku
CS Division of Molecular Immunology, Institute for Enzyme Research, University of Tokushima, Tokushima, Japan.. mitsuru@ier.tokushima-u.ac.jp
SO Journal of immunology (Baltimore, Md. : 1950), (2002 Aug 1) Vol. 169, No. 3, pp. 1151-8.
Journal code: 2985117R. ISSN: 0022-1767.

CY United States
DT Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
LA English
FS Abridged Index Medicus Journals; Priority Journals
EM 200208
ED Entered STN: 23 Jul 2002
Last Updated on STN: 30 Aug 2002
Entered Medline: 13 Aug 2002
AB NF-kappa B-inducing kinase (NIK) is involved in lymphoid organogenesis in mice through lymphotoxin-beta receptor signaling. To clarify the roles of NIK in T cell activation through TCR/CD3 and costimulation pathways, we have studied the function of T cells from aly mice, a strain with mutant NIK. NIK mutant T cells showed impaired proliferation and IL-2 production in response to anti-CD3 stimulation, and these effects were caused by impaired NF-kappa B activity in both mature and immature T cells; the impaired NF-kappa B activity in mature T cells was also associated with the failure of maintenance of activated NF-kappa B. In contrast, responses to costimulatory signals were largely retained in aly mice, suggesting that NIK is not uniquely coupled to the costimulatory pathways. When NIK mutant T cells were stimulated in the presence of a protein kinase C (PKC) inhibitor, proliferative responses were abrogated more severely than in control mice, suggesting that both NIK and PKC control T cell activation in a cooperative manner. We also demonstrated that NIK and PKC are involved in distinct NF-kappa B activation pathways downstream of TCR/CD3. These results suggest critical roles for NIK in setting the threshold for T cell activation, and partly account for the immunodeficiency in aly mice.